Extension Study to Evaluate Safety and Efficacy of Jaktinib in Patients With Active Ankylosing Spondylitis(AS)

An Open-Label, Multicenter, Extension Study to Assess the Long-Term Safety and Efficacy of Jaktinib in Patients With Active Ankylosing Spondylitis(AS)

The purpose of this study is to determine if Jaktinib is safe and effective in participants with active ankylosing spondylitis.

Inclusion Criteria:

• The investigators concluded that the participants continued to benefit from treatment with Jaktinib.
• The participants have been fully informed and voluntarily signed informed consent.
• The participants completed the ZGJAK029 study for 16 weeks of treatment and visitation and had good compliance.
• The interval between the participants' first dose and the last dose of ZGJAK029 ≤ 4 weeks.

Exclusion Criteria:

• There were any grade ≥3 adverse events within 4 weeks prior to enrollment and no return to grade 1 or normal.
• Within 4 weeks prior to enrollment, participants had the following infectious diseases: tuberculosis infection requiring treatment; HIV-positive, syphilis, HBV infection, HCV infection.
• The investigators considered participants unsuitable for this study.